DrugMonitor™ Anti-Briakinumab Antibody (VS-1224-YC221) (CAT#: VS-1224-YC221)
Briakinumab is a human anti-IL-12 monoclonal antibody being developed for T-cell-driven autoimmune diseases, aiming at treating psoriasis, multiple sclerosis, Crohn's Disease, and other autoimmune and inflammatory disorders. The DrugMonitor™ Anti-Briakinumab Antibody (VS-1224-YC221) is an anti-drug antibody (ADA) against Briakinumab. This drug-based antibody is raised in mice immunized with the Briakinumab. The anti-Briakinumab antibody may be used in ELISA, pharmacokinetics (PK), and pharmacodynamics (PD) analyses, or serves as a reference standard in ADA assays. It also is an excellent tool for therapeutic drug monitoring, allowing to evaluate the drug efficacy and determine the drug concentration of the Briakinumab in samples.
Specific Inquiry
Specifications
- Host Animal
- Mouse
- Specificity
- Briakinumab
- Target
- Briakinumab
- Immunogen
- Briakinumab
- Type
- Mouse IgG
- Species Reactivity
- Human
- Purity
- >95%
- Purification
- Protein G
- Applications
- ELISA, PK/PD, ADA control
- Format
- Liquid
- Concentration
- Batch-dependent
- Buffer
- PBS, pH 7.4
- Preservative
- No preservatives
- Storage
- Store at 4°C for 1-2 weeks and at -20°C for 1 year. Avoid repeated freezing and thawing.
- Generic name
- Briakinumab
- Drug Weight
- 146500.0 Da
- Formula
- C₆₃₇₆H₉₈₇₄N₁₇₂₂O₁₉₉₂S₄₄
- Related Disease
- psoriasis, multiple sclerosis, Crohn's Disease, and other autoimmune and inflammatory disorders
Downloads
Download resources about recombinant antibody development and antibody engineering to boost your research.
See other products for "Briakinumab"
Anti-Human IL12+IL23 Recombinant Antibody (Briakinumab)Recombinant monoclonal antibody to IL12+IL23. Briakinumab (ABT-874) is a human monoclonal antibody for the treatment of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. As of 2011 drug development for psoriasis has been discontinued in the U.S. and Europe. Like ustekinumab, the antibody targets the interleukins 12 and 23.
Afuco™ Anti-IL12+IL23 ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-103)This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to IL12+IL23. It is a human monoclonal antibody for the treatment of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. As of 2011 drug development for psoriasis has been discontinued in the U.S. and Europe. Like , the antibody targets the interleukins 12 and 23.
Customer Reviews and Q&As
There are currently no Customer reviews or questions for VS-1224-YC221. Click the button above to contact us or submit your feedback about this product.
Popular products with customers
Application: WB, FC, IP, ELISA, Neut, FuncS, IF
Application: IF, IP, Neut, FuncS, ELISA, FC, ICC
Application: WB, FC, IP, ELISA, Neut, FuncS, IF
-1.png)
Application: WB, ELISA
-1-1.png)
Application: ELISA
Application: ELISA, IHC, FC, IP, IF, FuncS
Application: ELISA, WB, Microarray, Block
-1.png)
Application: ELISA
Application: ELISA, FC, FuncS
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
